Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 5/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 6/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | FLT3 | P36888 | 2/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243868 | 0.85 | KRAS (0.46) | KRASTRPV1ESR1ESR2C5AR1 | |
| SCHEMBL21243935 | 0.81 | KRAS (0.61) | KRASC5AR1RPS6KB1GRM7 | |
| SCHEMBL25291151 | 0.80 | KRAS (0.41) | KRASTRPV1ESR1ESR2C5AR1 | |
| SCHEMBL30305262 | 0.80 | KRAS (0.41) | KRASTRPV1ESR1ESR2C5AR1 | |
| SCHEMBL21243933 | 0.79 | KRAS (0.56) | KRASTRPV1ESR1ESR2C5AR1 | |
| SCHEMBL21263722 | 0.77 | GRM7 (0.54) | KRASGRM7 | |
| SCHEMBL21243920 | 0.76 | KRAS (0.79) | KRAS | |
| SCHEMBL21243874 | 0.76 | KRAS (0.79) | KRAS | |
| SCHEMBL21243889 | 0.76 | KRAS (0.79) | KRAS | |
| SCHEMBL21217828 | 0.74 | TRPV1 (0.42) | KRASTRPV1ESR1ESR2C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749665-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2019155399-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | TOP2A, TOP1, TOP2B | KRAS 149/4885TRPV1 4448/4885ESR1 4471/4885 |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | TOP2A, TOP1, TOP2B | KRAS 149/4885TRPV1 4448/4885ESR1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.